Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
Leukemia
.
2024 Aug;38(8):1866.
doi: 10.1038/s41375-024-02311-w.
Authors
I Vaxman
1
2
3
,
S K Kumar
1
,
F Buadi
1
,
M Q Lacy
1
,
D Dingli
1
,
Y Hwa
1
,
A Fonder
1
,
M Hobbs
1
,
S Hayman
1
,
T Kourelis
1
,
R Warsame
1
,
E Muchtar
1
,
N Leung
1
,
P Kapoor
1
,
M Grogan
4
,
R Go
1
,
Y Lin
1
,
W Gonsalves
1
,
M Siddiqui
1
,
R A Kyle
1
,
S V Rajkumar
1
,
M A Gertz
1
,
A Dispenzieri
5
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
2
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
3
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
4
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
5
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
[email protected]
.
PMID:
38886493
PMCID:
PMC11286503
DOI:
10.1038/s41375-024-02311-w
No abstract available
Publication types
Published Erratum